NicOx S.A.

NicOx is building an international late-stage development and commercial Ophthalmology Company based around therapeutics, diagnostics and devices.

NicOx is also applying its proprietary nitric oxide (NO)-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases. The Company’s pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb and Ferrer.

NicOx’s strategic partnerships with some of the world’s leading pharmaceutical and specialty pharmaceutical companies enable it to maximize the value of its R&D platform and broad portfolio, while allowing the Company to retain future commercialization rights in select areas.